Treating Carcinomas Using Immunotoxin Specific for Cancer Stem Cells
BENEFITS OF TARGETING CANCER STEM CELLS WITH NOVEL IMMUNOTOXIN ΓÇó Greater sensitivity allows better detection, identification, and targeting of CSCsΓÇó Single chain variable fragment (scFv) of antibody decreases immunogenicityΓÇó Immunotoxin depletion of CSC may serve as monotherapy or adjuvant therapyΓÇó Immunotoxin targeting of multiple proteins provides greater specificity towards CSCs with minimal effect on normal cells
IMMUNOTOXIN FOR CANCER STEM CELLSTARGETING CANCER STEM CELLS TO PREVENT TUMOR RECURRENCECarcinomas are invasive malignant tumors of transformed epithelial cells. It has been proposed that tumor cells derive from a small population of cancer stem cells (CSCs) ΓÇô self-generating progenitor cells that can migrate, replicate, and differentiate into mature cancer cells. CSCs appear resistant to chemotherapy drugs and radiation treatment. Although the majority of cancer cells may be destroyed with traditional treatment, tumor recurrence is likely due to CSC survival. Thus, therapeutic applications may benefit from targeting this cancer cell population. DESTROYING CANCER STEM CELLS WITH AN IMMUNOTOXIN SPECIFIC FOR CD133An immunotoxin is an antibody that is linked to a toxin. Using a mechanism unrelated to conventional chemotherapeutic agents, the immunotoxin kills only cells that express the protein specific for the antibody. Thus, immunotoxins can be tuned to recognize proteins restricted to certain cell types. A monoclonal antibody directed at CD133, a glycoprotein accepted as a CSC marker, has been shown to arrest tumor progression in animal models of breast and head/neck carcinomas. Furthermore, bispecific ligand immunotoxins show greater specificity and enhancement of treatment. Combining a CSC-directed immunotoxin with traditional cancer therapy may reduce tumor recurrence and improve patient outcome.BENEFITS OF TARGETING CANCER STEM CELLS WITH NOVEL IMMUNOTOXIN ΓÇó Greater sensitivity allows better detection, identification, and targeting of CSCsΓÇó Single chain variable fragment (scFv) of antibody decreases immunogenicityΓÇó Immunotoxin depletion of CSC may serve as monotherapy or adjuvant therapyΓÇó Immunotoxin targeting of multiple proteins provides greater specificity towards CSCs with minimal effect on normal cells
Inventor: OHLFEST, John, R. | PANYAM, Jayanth | SWAMINATHAN, Suresh, Kumar | VALLERA, Daniel, A.
Priority Number: WO2011149493A1
IPC Current: C07K001628 | A61K0039395 | C07K001630 | C07K001900 | G01N003353
Assignee Applicant: Regents of the University of Minnesota
Title: SINGLE -CHAIN VARIABLE FRAGMENT ANTI-CD133 ANTIBODIES AND USES THEREOF | ANTICORPS ANTI-CD133 À FRAGMENTS MONOCATÉNAIRES VARIABLES ET LEURS UTILISATIONS
Usefulness: SINGLE -CHAIN VARIABLE FRAGMENT ANTI-CD133 ANTIBODIES AND USES THEREOF | ANTICORPS ANTI-CD133 À FRAGMENTS MONOCATÉNAIRES VARIABLES ET LEURS UTILISATIONS
Summary: The Hybridoma Clone 7 is used for producing monoclonal antibody comprising scFv. The Hybridoma Clone 7, monoclonal antibody, and scFv are used in a composition for administration to a subject (claimed). It can be used for the detection and treatment of certain forms of cancer such as brain tumors (e.g., glioblastomas and astrocytomas), muscle tumors (e.g. sarcomas), and/or various carcinoma such as breast cancer, pancreatic cancer, head and neck cancer, prostate cancer, and colon cancer.
Novelty: New hybridoma identified as Hybridoma Clone 7, useful for producing monoclonal antibody for a composition for administration to a subject, e.g. for treating cancer, e.g. breast cancer, pancreatic cancer, and colon cancer
診斷/治療
癌症/腫瘤
美國
